A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment
Clinical trial NCT06987500 · RECRUITING
Trial details
- NCT number
- NCT06987500
- Sponsor
- Evopoint Biosciences Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-11
- Primary completion
- 2027-02-14
- Enrollment
- 132
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.